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Background
Multiple sclerosis (MS) is the most prevalent chronic inflammatory disease of the central 
nervous system, affecting more than 2 million people worldwide [1] and remains the major 
cause of neurological disability in young adults [1,3]. MS often leads to significant accumu-
lated disability over its typical 30-40-year course although the course is highly variable.
MS is associated to a high economic burden, with an estimated annual cost of approxi-
mately $ 10 billion in USA [4,5]. MS reported high direct costs associated to the health care 
resources consumption, but also high indirect costs associated to informal care, services and 
loss of productivity [5]. The direct and indirect costs are associated to the disability status of 
MS patients, with increased costs associated to increased disability [5]. The introduction of 
disease-modifying therapies (DMTs) over the past two decades has had profound effects on 
the management of Relapsing Multiple Sclerosis (RMS), reducing the progression of the dis-
ease and changing the cost drivers in the low level of disability [5-7]. However, there is still 
need of new effective and safe treatment to improve the management of RMS and avoiding 
the development of high disability level [7].
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aBstract
INTRODUCTION: The availability of ocrelizumab for the relapsing forms of multiple sclerosis (MS) in the Italian markets 
raised some questions about its economic impact and value compared to the alternative treatment options available.
AIM: To assess the cost-effectiveness and budget impact of ocrelizumab compared to the most used second line disease 
modifying therapies (DMTs) in Italy.
METHODS: The study was divided in two phases: Phase 1 – based on the development of a decision analytical Markov 
model to assess the cost-effectiveness of ocrelizumab compared to natalizumab and fingolimod, and Phase 2 – based on 
the development of a budget impact model to assess the economic impact of ocrelizumab in Italy. Both models used the 
National Health System perspective; a lifetime horizon was applied in the cost-effectiveness analysis and a 3-year time 
horizon in the budget impact. The cost-effectiveness analysis results were reported as incremental cost-effectiveness ratio 
(ICER) expressed as € per Quality Adjusted Life Year (QALY) gained, the budget impact analysis results were reported as 
difference in the overall budget (€) between a scenario with and without ocrelizumab.
RESULTS: The two analyses reported ocrelizumab as a cost-effective option compared to natalizumab and fingolimod with 
a positive impact on the overall NHS budget. In the base-case analysis, the ICER was € 2,023 for ocrelizumab compared 
to fingolimod; while ocrelizumab resulted cost-saving compared to natalizumab. The sensitivity analysis confirmed the 
base-case analysis results. Further, the use of ocrelizumab was associated to a budget decrease of € 21 million (-2.6%) in 
a 3-year time horizon.
CONCLUSION: The results of our cost-effectiveness and budget impact models reported ocrelizumab as an effective and 
efficient treatment in patients with relapsing forms of MS who failed a first line DMTs from the Italian NHS perspective. 
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In this scenario, ocrelizumab is a humanized anti-CD20 monoclonal antibody recently 
approved in Italy for the treatment of adults with RMS and with primary progressive form 
(PPMS). In the 96-week OPERA I and OPERA II trials, patients with RMS and treated with 
ocrelizumab significantly reduced annualized relapse rates and disability progression versus 
interferon β-1a [8]. The availability of this new DMT in the market raised some questions 
about its value compared to the alternative treatment options and its economic impact. To fill 
this gap, we aimed to assess the cost-effectiveness and budget impact of ocrelizumab com-
pared to most used second line treatment options available in Italy.
Methods
The study was divided in two phases: Phase 1 – based on the development of a decision 
analytical Markov model to assess the cost-effectiveness of ocrelizumab, and Phase 2 – based 
on a budget impact model to assess the economic impact associated to the market access of 
ocrelizumab in Italy.
Phase 1: Cost-Effectiveness Analysis
The cost-effectiveness analysis was based on a Markov model developed to assess ocreli-
zumab in patients with RMS who failed a first line treatment. The model simulated the natural 
history of RMS based on four main clinical events: disability progression, relapse, develop-
ment of progressive form, and death. The Expanded Disability Status Scale (EDSS) score 
defined the level of disability and its progression. The model included the impact of ocreli-
zumab and other DMTs applying a reduction in the disability progression and relapse rate 
with positive effects on the patient’s health and quality of life. The model also simulated the 
cost associated to the RMS management and the cost associated to DMTs. 
Figure 1 reports the model structure. The health states were defined based on the EDSS 
score, with each level of EDSS representing one health state. This approach was in line with 
previous models developed to assess DMTs in RMS [9]. At the beginning of the simulation, 
the RMS patients reported an EDSS level within 0 and 6.5. During the simulation, these pa-
tients could develop a higher or lower EDSS level or the Secondary Progressive Multiple 
Sclerosis (SPMS) course. When simulated patients developed SPMS, the model not allows 
moving back to the RMS. Further, as done for the RMS, the SPMS severity was defined by 
the EDSS level [9]. The SPMS patients could experience an EDSS level between 2 and 9 and 
move to higher EDSS level during the simu-
lation. All the DMTs included in the model 
could reduce the disability progression and 
the relapse rate in RMS patients. Further, the 
model assumes an effect of DMTs in reduc-
ing the development of SPMS. The DMTs 
interruption was assumed when patients de-
veloped an EDSS level equal or higher than 
seven or when they developed SPMS.
In the model, the disability progression 
probability and relapse rate were kept con-
stant over time and were specific for the MS 
phenotype (RMS or SPMS) and EDSS level. 
The mortality rates applied in the model 
were specific for age, sex and EDSS level. 
No direct effect on mortality was associated 
to DMTs, but an indirect effect was assumed 
based on the treatment effect in reducing 
disease progression to higher EDSS level, 
that were associate to a higher probability of 
death.
In this cost-effectiveness analysis, the 
model compared ocrelizumab (Ocrevus®, 
Roche S.p.A.) with the most frequent used 
second line DMTs: fingolimod (Gilenya®, 
Novartis Farma S.p.A.) and natalizumab 
(Tysabri®, Biogen Italia s.r.l.). The model es-
timated costs and benefits of each treatment 
Figure 1. Cost-effectiveness model structure. Grey arrows show the possible 
direction of EDSS level changes during the simulation; Grey squares in the “RMS, 
treated” health states represent the EDSS level where the diseases modifying 
treatments are not provided; Grey squares in the “SPMS, untreated” health states 
represent the EDSS level not allow in the simulation for the SPMS type
RMS = relapsing remitting multiple sclerosis; SPMS = secondary progressive multiple 
sclerosis.
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and expressed outcomes in terms of 2019 euro (€), life-years (LYs), quality-adjusted life-
years (QALYs), and incremental cost-effectiveness ratios (ICERs) expressed as € per QALY 
gained.
We discounted costs and benefits at an annual 3% rate [10,11] and performed the analysis 
from an Italian National Health System (NHS) perspective. The model adopted a lifetime 
horizon and used a 1-year cycle length for the simulation.
Clinical Data
The simulated cohort in the cost-effectiveness analysis reflected the mean age, gender and 
EDSS distribution reported in the OPERA I and OPERA II trials [8] (Table I).
The probabilities of EDSS changes in RMS were estimated from the British Columbia 
Multiple Sclerosis database [20]. Estimates of the probability of moving from RMS to SPMS 
for each EDSS level and the probability of the transition among EDSS level in SPMS patients 
derived from the London Ontario database [12-16] (Table I). A specific relapse probability for 
each EDSS level was estimated for both RMS and SPMS and were estimated combining the 
data by Patzold et al. [15] with data reported in the UK MS Survey [17] (Table I).
The mortality probabilities associated to MS were based on the high mortality rates re-
ported by MS patients compared to the general population [18,19]. The specific Italian general 
population mortality rates, stratified by age and sex [23], were adjusted by mortality relative 
risk reported by Pokorski et al. [19] for each EDSS level (Table I). These relative risks were 
estimated comparing the mortality risk of MS in each EDSS level with the mortality rate in 
the general population, adjusting for age and sex [19].
Treatment Effectiveness
In this cost-effectiveness analysis, ocrelizumab was compared with the most used second 
line DMTs in Italy (fingolimod and natalizumab). These treatments modify the natural history 
of RMS i) slowing down the disease progression to higher EDSS level, ii) reducing the relapse 
rate, and iii) reducing the progression to SPMS.
A recently published Network Meta-Analysis (NMA) [24], based on DMTs clinical trials, 
reported the relative risk (RR) of annual relapse rate of each treatment compared to placebo 
(Table II). Further, using the placebo as reference, the NMA estimated the efficacy of each 
treatment in reducing the disability progression. The treatment efficacy was reported as Haz-
ard ratio (HR) using the Confirmed Disability Progression (CDP) at 12 weeks (Table II). To 
estimate the reduction of relapse rate and disease progression associated to each treatment, we 
applied the RR and HR estimated in the NMA to the natural history probabilities.
Parameters Value
Source
EDSS 0 1 2 3 4 5 6 7 8 9
Cohort characteristics
Age (years) 37.0 [8]
Male (%) 34.0 [8]
Disability distribution (%) 3.08 18.85 30.45 23.50 14.74 8.76 0.60 - - - [8]
Clinical data (annual probability)
Developing SPMS 0.000 0.045 0.074 0.094 0.119 0.151 0.189 0.237 0.295 1.000 [12-16]
Relapse – RMS 0.710 0.730 0.680 0.720 0.710 0.590 0.490 0.510 0.510 0.510 [15,17]
Relapse – SPMS - - 0.470 0.880 0.550 0.520 0.450 0.340 0.340 0.340 [15,17]
Mortality (RR) –RMS and 
SPMS
1.000 1.430 1.600 1.640 1.670 1.840 2.270 3.100 4.450 6.450 [18,19]
Quality of life (utility)
RMS 0.923 0.882 0.836 0.777 0.783 0.755 0.718 0.579 0.310 0.040 [21]
SPMS 0.878 0.837 0.791 0.732 0.738 0.710 0.673 0.534 0.265 -0.005 [5,21]
Costs (overall management)
RMS (€) 1,906 1,906 1,906 1,906 3,983 3,983 3,983 9,468 9,468 9,468 [22]
SPMS (€) 5,347 5,347 5,347 5,347 9,642 9,642 9,642 9,517 9,517 9,517 [22]
Table I. Clinical, quality of life and costs data input
EDSS = the Expanded Disability Status Scale; RMS = Relapsing Multiple Sclerosis; RR = relative risk; SPMS = Secondary Progressive Multiple Sclerosis
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Using a conservative approach, considering the efficacy of ocrelizumab in the MS pro-
gressive phenotypes, we assumed no treatments efficacy in SPMS. Further, we assumed the 
probability of treatment interruption for any causes reported by the NMA [24]. This approach 
gave the possibility to account for both adverse events (AEs) and reduction of efficacy (Table 
II). The simulated patients moved to the “not treated status” when they discontinued the treat-
ment. The probabilities of main adverse events for each treatment were retrieved form the 
NMA (see Supplementary Files, Table I) [24]. Finally, we also included the most important 
DMTs AEs based on the clinical experts’ opinion.
Quality of Life
Specific Italian utility values for each EDSS level derived from Battaglia et al. [21]; while 
the disutility associates to a relapse event was retrieved by Kobelt et al. [5] and assumed 
equal to -0.18 in all EDSS levels. The relapse disutility was estimated as a difference between 
patients who experienced a relapse and patients who do not reported any relapse in the survey 
conducted by Kobelt et al. The model assumed relapse duration of 46 days. 
The utility for each EDSS level in the SPMS patients was estimated subtracting 0.045 to 
the RMS utility values (Table I). The utility reduction was estimated from the date reported in 
Orme et al. [17]. Further, the AEs disutility was estimated based on the health care resources 
consumption reported in two NICE appraisals on MS treatment (see Supplementary Files, 
Table I) [25,26].
Cost Data
The cost-effectiveness analysis was conducted from the Italian NHS perspective, there-
fore, we included the costs associated to the overall disease management for each EDSS level, 
the DMTs treatment cost (drug costs + treatment follow-up costs), and the cost due to relapses.
The MS management cost was retrieved by an Italian cost-of-illness study [22]. Table 
I reports the cost for each EDSS level, excluding the DMTs costs that are accounted in the 
model as a specific and independent parameter. The costs were adjusted for the inflation rate 
reported in Italy and estimated as € in 2018 [27].
As already reported, the management costs were estimated for each EDSS level, exclud-
ing the costs associated to the DMTs, and include hospitalizations, pharmacological therapies, 
outpatient visits, and diagnostic exams not associated to DMTs. The DMTs costs were con-
sidered only in RMS patients with EDSS < 7 in the treatment status and include drug costs, 
administration costs, and outpatient visits, laboratory and diagnostic examinations associated 
to the treatment follow-up.
The DMT cost was estimated as annual treatment cost, based on ex-factory price [28] 
(Table III). The final DMTs cost was estimated including the statutory and hidden discounts.
The administration cost of injectable DMTs was € 11.6 per administration [29]. The annu-
al treatment follow-up costs were estimated for each DMT based on the health care resources 
consumption reported in the Emilia Romagna Region guidelines and on the national tariff 
reported by AGENAS [29-31]. The relapse cost was retrieved by an Italian cost-of-illness 
study and set to € 405 per relapse [22]. Further, the AEs costs were estimated based on the 
health care resources consumption reported in two NICE appraisals on MS treatments (see 
Supplementary Files, Table I). [25,26].
Outcome
The model estimated the costs (€), the life years and the QALYs gained for each DMT 
included in the analysis. The cost-effectiveness results were reported as incremental cost-
effectiveness ratio (ICER) per QALY gained. The ICER was estimated comparing ocreli-
zumab with natalizumab and fingolimod. An ICER under the willingness-to-pay threshold of 
40,000€ per QALY gained was considered cost-effective [37].
DMT
ARR CDP-12 weeks Discontinuation
RR SE hR SE Annual probability SE
Fingolimod 0.472 0.078 0.777 0.119 0.063 0.006
Natalizumab 0.376 0.105 0.536 0.176 0.022 0.002
Ocrelizumab 0.306 0.125 0.432 0.235 0.062 0.006
Table II. Disease-modifying therapies (DMTs) efficacy and discontinuation probability [24]
ARR = annualized relapse rate; CDP = confirmed disability progression; HR, Hazard ratio; RR = relative risk; SE = standard error
DMT Dosage Package
list 
price (€)
net 
price (€)
Source
Follow-up 
1st year 
(€)
Follow-up 
after 1st 
year (€)
Source
Fingolimod 0.5 mg qd, PO 28 capsules 0.5 mg 2,681 1,624 [28] 1,203 309 [29-31]
Natalizumab 300 mg every 
4 weeks, IV
300 mg/15 ml, 1 unit 2,681 1,624 [28] 1,737 937
Ocrelizumab 600 mg every 
6 months, IV
300 mg/10 ml, 1 unit 9,309 5,641 [28] 1,150 363
Alemtuzumab 12 mg/day for 5 days 
(first cycle); after 12 
months, 12 mg/day 
for 3 days (second 
cycle), IV
12mg/1.2 ml, 1 vial 13,126 7,953 [28] 2,105 1,233
Table III. Disease-modifying therapies (DMTs) costs 
IV = intravenous administration; PO = per os (oral administration); qd = quaque die (once a day)
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Using a conservative approach, considering the efficacy of ocrelizumab in the MS pro-
gressive phenotypes, we assumed no treatments efficacy in SPMS. Further, we assumed the 
probability of treatment interruption for any causes reported by the NMA [24]. This approach 
gave the possibility to account for both adverse events (AEs) and reduction of efficacy (Table 
II). The simulated patients moved to the “not treated status” when they discontinued the treat-
ment. The probabilities of main adverse events for each treatment were retrieved form the 
NMA (see Supplementary Files, Table I) [24]. Finally, we also included the most important 
DMTs AEs based on the clinical experts’ opinion.
Quality of Life
Specific Italian utility values for each EDSS level derived from Battaglia et al. [21]; while 
the disutility associates to a relapse event was retrieved by Kobelt et al. [5] and assumed 
equal to -0.18 in all EDSS levels. The relapse disutility was estimated as a difference between 
patients who experienced a relapse and patients who do not reported any relapse in the survey 
conducted by Kobelt et al. The model assumed relapse duration of 46 days. 
The utility for each EDSS level in the SPMS patients was estimated subtracting 0.045 to 
the RMS utility values (Table I). The utility reduction was estimated from the date reported in 
Orme et al. [17]. Further, the AEs disutility was estimated based on the health care resources 
consumption reported in two NICE appraisals on MS treatment (see Supplementary Files, 
Table I) [25,26].
Cost Data
The cost-effectiveness analysis was conducted from the Italian NHS perspective, there-
fore, we included the costs associated to the overall disease management for each EDSS level, 
the DMTs treatment cost (drug costs + treatment follow-up costs), and the cost due to relapses.
The MS management cost was retrieved by an Italian cost-of-illness study [22]. Table 
I reports the cost for each EDSS level, excluding the DMTs costs that are accounted in the 
model as a specific and independent parameter. The costs were adjusted for the inflation rate 
reported in Italy and estimated as € in 2018 [27].
As already reported, the management costs were estimated for each EDSS level, exclud-
ing the costs associated to the DMTs, and include hospitalizations, pharmacological therapies, 
outpatient visits, and diagnostic exams not associated to DMTs. The DMTs costs were con-
sidered only in RMS patients with EDSS < 7 in the treatment status and include drug costs, 
administration costs, and outpatient visits, laboratory and diagnostic examinations associated 
to the treatment follow-up.
The DMT cost was estimated as annual treatment cost, based on ex-factory price [28] 
(Table III). The final DMTs cost was estimated including the statutory and hidden discounts.
The administration cost of injectable DMTs was € 11.6 per administration [29]. The annu-
al treatment follow-up costs were estimated for each DMT based on the health care resources 
consumption reported in the Emilia Romagna Region guidelines and on the national tariff 
reported by AGENAS [29-31]. The relapse cost was retrieved by an Italian cost-of-illness 
study and set to € 405 per relapse [22]. Further, the AEs costs were estimated based on the 
health care resources consumption reported in two NICE appraisals on MS treatments (see 
Supplementary Files, Table I). [25,26].
Outcome
The model estimated the costs (€), the life years and the QALYs gained for each DMT 
included in the analysis. The cost-effectiveness results were reported as incremental cost-
effectiveness ratio (ICER) per QALY gained. The ICER was estimated comparing ocreli-
zumab with natalizumab and fingolimod. An ICER under the willingness-to-pay threshold of 
40,000€ per QALY gained was considered cost-effective [37].
DMT
ARR CDP-12 weeks Discontinuation
RR SE hR SE Annual probability SE
Fingolimod 0.472 0.078 0.777 0.119 0.063 0.006
Natalizumab 0.376 0.105 0.536 0.176 0.022 0.002
Ocrelizumab 0.306 0.125 0.432 0.235 0.062 0.006
Table II. Disease-modifying therapies (DMTs) efficacy and discontinuation probability [24]
ARR = annualized relapse rate; CDP = confirmed disability progression; HR, Hazard ratio; RR = relative risk; SE = standard error
DMT Dosage Package
list 
price (€)
net 
price (€)
Source
Follow-up 
1st year 
(€)
Follow-up 
after 1st 
year (€)
Source
Fingolimod 0.5 mg qd, PO 28 capsules 0.5 mg 2,681 1,624 [28] 1,203 309 [29-31]
Natalizumab 300 mg every 
4 weeks, IV
300 mg/15 ml, 1 unit 2,681 1,624 [28] 1,737 937
Ocrelizumab 600 mg every 
6 months, IV
300 mg/10 ml, 1 unit 9,309 5,641 [28] 1,150 363
Alemtuzumab 12 mg/day for 5 days 
(first cycle); after 12 
months, 12 mg/day 
for 3 days (second 
cycle), IV
12mg/1.2 ml, 1 vial 13,126 7,953 [28] 2,105 1,233
Table III. Disease-modifying therapies (DMTs) costs 
IV = intravenous administration; PO = per os (oral administration); qd = quaque die (once a day)
Sensitivity analyses
A series of sensitivity analyses were per-
formed to assess the reliability of model re-
sults. An alternative scenario was assessed 
using the CDP-24 weeks instead of CDP-12 
based on the data reported in the NMA [24]. 
A second alternative scenario was assessed 
using the society’s perspective to include the 
possible impact of ocrelizumab on the direct 
non-medical costs and the indirect costs com-
pare to the other DMTs included. These costs 
were retrieved by Battaglia et al. for each 
EDSS level [21] (see Supplementary Files, 
Table II). Further, a one-way sensitivity analy-
sis was performed to assess the impact of each 
parameter on the model results and a probabi-
listic sensitivity analysis was performed to as-
sess the impact of all parameters uncertainty.
Phase 2: Budget Impact Analysis
The analysis was based on a Budget Impact model developed to assess the economic im-
pact of ocrelizumab on the RMS management in the Italian market. The model estimated the 
costs associated to MS management in a scenario where ocrelizumab was not available (Sce-
nario No-Ocre) compared to a scenario where ocrelizumab was available (Scenario Ocre).
The model was based on epidemiological data of RMS in Italy and on the second-line 
DMTs market share. The model estimated the RMS patients in Italy treated with a second line 
DMTs (alemtuzumab, fingolimod and natalizumab) or with a rapidly evolving severe RMS. 
The model estimated the number of patients treated with each DMT and the associated costs 
using 3-year time horizon and from the Italian NHS perspective. Based on the NHS point of 
view, the model included the cost of DMTs, follow-up (outpatient visits, laboratory tests, and 
diagnostic exams) and AEs management.
Population
The model estimated the Italian MS population using an average prevalence of 141.7 per 
100,000 population [32,33], a yearly incidence of 5.7 per 100,000 person-years [32] and a 
mortality rate of 0.49 per 100,000 person-years [33,34] (Table IV). Based on the MS popula-
tion, the model estimates the number of RMS patients and the number of patients with rap-
idly evolving severe RMS (Table IV). The rapidly evolving patients and the RMS patients 
treated with alemtuzumab, fingolimod and natalizumab were combined to estimate the target 
population of ocrelizumab budget impact analysis (Table IV). In the 3 years simulated, we 
assumed no change in the incidence and mortality rate.
Costs
Considering the Italian NHS perspective, we included the following cost: i) DMTs cost, ii) 
monitoring and follow-up costs, and iii) AEs costs.
Parameter Value Source
Italian population (n.) 60,665,551 [35]
MS prevalence 143 per 100,000 population [32,33]
MS incidence 5.7 per 100,000 person-years [32]
MS mortality 0.49 per 100 person-years [33,34]
RMS prevalence within MS 
patients (%)
79.3 [36]
Rapidly evolving severe RMS 
prevalence, within RMS (%)
10.0 [36]
Patients treated with DMTs (%) 63.9 [36]
Patients treated with 
alemtuzumab, fingolimod and 
natalizumab, within treated 
patients (%)
19.5 [32]
Table IV. Target population of the budget impact analysis
DMTs = Disease-modifying therapies; MS = multiple sclerosis; RMS = relapsing multiple 
sclerosis
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The cost associated to relapses and EDSS level were not included in the budget impact 
analysis due to the low cost of relapse [22] and to the short time horizon assumed for this 
analysis that not allowed observing a significant impact in the EDSS progression of the dif-
ferent simulated treatments.
The DMTs costs are reported in Table III. The monitoring and follow-up costs used in the 
budget impact model are the same described for the cost-effectiveness analysis (Table III).
Further, also the AEs costs are the same used in the cost-effectiveness analysis [24-26] 
(see Supplementary Files, Table I).
Market share
The market share in the Scenario No-Ocre was estimated based on the DMTs utilization 
in Italy and reported in the Barometro 2017 report [32] in which, alemtuzumab, fingolimod 
and natalizumab were the 24.3% of all DMTs used in Italy (Table IV). Of these three DMTs, 
fingolimod was the most used and alemtuzumab the less frequent one (Table V). This market 
distribution was assumed constant over the 3 years simulation.
In the Scenario-Ocre, we assumed a 15% use of ocrelizumab in the first year, 30% in the 
second year and 45% in the third year (Table V). The increasing use of ocrelizumab was bal-
anced by the reduction of natalizumab and fingolimod. No change in the alemtuzumab market 
share was assumed in the Scenario-Ocre over the 3 years simulated.
In the analysis, we assumed a constant rate of treatment switch over each simulated year. 
Further, in the model we assumed a yearly treatment discontinuation probability of 12.1% 
[22].
Outcome
Based on the costs and health care resources consumption, the model estimated the total 
annual cost per patient per each treatment. The estimated annual costs were combined with 
Market share (%)
DMT
Year 1 Year 2 Year 3
Scenario w/o 
ocrelizumab
Scenario w/ 
ocrelizumab
Scenario w/o 
ocrelizumab
Scenario w/ 
ocrelizumab
Scenario w/o 
ocrelizumab
Scenario w/ 
ocrelizumab
Ocrelizumab - 15 - 30 - 45
Fingolimod 60 50 60 45 60 37,5
Natalizumab 35 30 35 20 35 12,5
Alemtuzumab 5 5 5 5 5 5
Table V. Disease-modifying therapies (DMT) market share in the 3 simulated years
the epidemiological and market share data to estimate the 3 years overall cost of the Scenario 
with and without ocrelizumab. The difference between these two scenarios was estimated to 
assess the budget impact of ocrelizumab in Italy over a 3-year time horizon.
results
Cost-Effectiveness Analysis
In the base case scenario, ocrelizumab resulted as the most effective treatment with 0.504 
QALYs gained compare to natalizumab and 1.306 QALYs compare to fingolimod (Table VI). 
Further, ocrelizumab was less expensive than natalizumab and with an incremental cost of € 
2,645 compared to fingolimod. Comparing ocrelizumab with fingolimod, the ICER estimated 
was € 2,023 per QALY gained, while ocrelizumab resulted cost-saving (less expensive and 
more effective) compared to natalizumab.
In the alternative scenario 1, using the CDP-24 weeks as effectiveness outcome, ocreli-
zumab resulted cost-saving compared to fingolimod and cost-effective compared to natali-
zumab (Table VI). Further, using the society perspective, that includes the high non-medical 
and -indirect costs associated to MS (Alternative scenario 2) [21], ocrelizumab resulted less 
expensive and more effective, when compared to both fingolimod and natalizumab (Table 
VI).
The results of the one-way sensitivity analysis reported that ocrelizumab is always the 
cost-effective option compared to ocrelizumab and fingolimod. These results were confirmed 
by the probabilistic sensitivity analysis (Figure 2) where ocrelizumab reported a 99% prob-
ability to be cost-effectiveness at a willingness to pay threshold of €40,000 per QALY gained. 
Budget impact analysis
Our model estimated a target population of RMS equal to 14,966 patients in the first year, 
15,462 in the second year and 15,955 in the third year. The number of patients treated with 
each DMT in the two scenarios is reported in Supplementary Files, Figure 1. Fingolimod re-
ported the higher number of patients treated in the Scenario No-Ocre (8,980 first year, 8,277 
second year, and 9,573 third year); while in the scenario with ocrelizumab, fingolimod was 
the most used therapy only in the first and second year and ocrelizumab in the third year. 
In the base case analysis, the total economic impact of ocrelizumab patients with RMS was 
estimated at € 21 million in the 3 years simulated, with an overall budget reduction of 2.6% 
(Figure 3). The model reported a budget reduction due to ocrelizumab of 1.01% (-€ 2.64 
millions) in the first year, 2.51% (-€ 6.77 millions) in the second year, and 4.20% (-€ 11.69 
millions) in the third year.
DMT Costs (€) Δ Costs (€) lYs Δ LYs QAlYs Δ QALYs ICER
1 (€ per 
QAlY gained)
Base-case scenario
Ocrelizumab  253,842 - 21.704 - 12.706 - -
Natalizumab  306,798 -52,956 21.628 0.076 12.200 0.506 Dominant
Fingolimod  251,197 2,645 21.423 0.281 11.399 1.308  2,023
Alternative scenario 1 – CDP-24 weeks as effectiveness outcome
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Natalizumab  317,173 -65,030 21.783 -0.140 12.820 -0.386 168,4212
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Ocrelizumab  827,194 - 21.704 - 12.706 - -
Natalizumab  902,324 -75,147 21.628 0.076 12.200 0.506 Dominant
Fingolimod  887,203 -60,009 21.423 0.281 11.399 1.308 Dominant
Table VI. Cost-effectiveness analysis results
CDP = confirmed disability progression; Dominant = ocrelizumab more effective and less expensive; ICER = incremental cost-effectiveness ratio; LYs = 
life years; QALYs = Quality Adjusted Life Years
1 ICER estimated comparing ocrelizumab vs other DMTs
2 ICER estimated comparing natalizumab vs ocrelizumab due to the high cost and effectiveness reported by natalizumab in the Alternative scenario 1
Figure 2. Cost-effectiveness acceptability curves
67Farmeconomia. Health economics and therapeutic pathways 2019; 20(1)
P. A. Cortesi, D. Paolicelli, M. Capobianco, P. Cozzolino, L. G. Mantovani
the epidemiological and market share data to estimate the 3 years overall cost of the Scenario 
with and without ocrelizumab. The difference between these two scenarios was estimated to 
assess the budget impact of ocrelizumab in Italy over a 3-year time horizon.
results
Cost-Effectiveness Analysis
In the base case scenario, ocrelizumab resulted as the most effective treatment with 0.504 
QALYs gained compare to natalizumab and 1.306 QALYs compare to fingolimod (Table VI). 
Further, ocrelizumab was less expensive than natalizumab and with an incremental cost of € 
2,645 compared to fingolimod. Comparing ocrelizumab with fingolimod, the ICER estimated 
was € 2,023 per QALY gained, while ocrelizumab resulted cost-saving (less expensive and 
more effective) compared to natalizumab.
In the alternative scenario 1, using the CDP-24 weeks as effectiveness outcome, ocreli-
zumab resulted cost-saving compared to fingolimod and cost-effective compared to natali-
zumab (Table VI). Further, using the society perspective, that includes the high non-medical 
and -indirect costs associated to MS (Alternative scenario 2) [21], ocrelizumab resulted less 
expensive and more effective, when compared to both fingolimod and natalizumab (Table 
VI).
The results of the one-way sensitivity analysis reported that ocrelizumab is always the 
cost-effective option compared to ocrelizumab and fingolimod. These results were confirmed 
by the probabilistic sensitivity analysis (Figure 2) where ocrelizumab reported a 99% prob-
ability to be cost-effectiveness at a willingness to pay threshold of €40,000 per QALY gained. 
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each DMT in the two scenarios is reported in Supplementary Files, Figure 1. Fingolimod re-
ported the higher number of patients treated in the Scenario No-Ocre (8,980 first year, 8,277 
second year, and 9,573 third year); while in the scenario with ocrelizumab, fingolimod was 
the most used therapy only in the first and second year and ocrelizumab in the third year. 
In the base case analysis, the total economic impact of ocrelizumab patients with RMS was 
estimated at € 21 million in the 3 years simulated, with an overall budget reduction of 2.6% 
(Figure 3). The model reported a budget reduction due to ocrelizumab of 1.01% (-€ 2.64 
millions) in the first year, 2.51% (-€ 6.77 millions) in the second year, and 4.20% (-€ 11.69 
millions) in the third year.
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discussion
Ocrelizumab is a humanized anti-CD20 monoclonal antibody recently approved in Italy 
for the treatment of adults with RMS and PPMS. In our study we compared this new treat-
ment option with the most used second-line DMTs in Italy, in order to estimate ocrelizumab 
cost-effectiveness in RMS patients. Further, to provide a complete picture of the economic 
impact of this new DMT, we assessed the possible budget impact associated to its use in the 
Italian market.
In two analyses conducted, ocrelizumab resulted cost-effective compared to natalizumab 
and fingolimod with a positive impact on the overall Italian NHS budget. In the base-case 
analysis the ICER per QALY gained was € 2,023 for ocrelizumab compared to fingolimod, 
while ocrelizumab resulted cost-saving compared to natalizumab. The sensitivity analysis 
confirmed the results. Further, the use of ocrelizumab in Italy was associated to a budget 
decrease of € 21 million in a 3-year time horizon, with an overall budget reduction of 2.6%.
To our knowledge, our analyses are the first conducted to determinate the cost-effective-
ness and budget impact of ocrelizumab in Italy. Our cost-effectiveness results are in line with 
previous analyses conducted in other countries [38-40]. The Scottish medicines Consortium 
(SMC) reported ocrelizumab as the cost-effectiveness option compare to natalizumab and 
fingolimod [38]. Using the CDP-12 and CDP-24 as treatment efficacy outcomes, ocrelizumab 
resulted cost-saving and cost-effective compared to natalizumab and reported an ICER be-
tween £ 1,400 and £ 4,000 per QALY gained compare to fingolimod. In a cost-effectiveness 
study conducted in US, ocrelizumab resulted more effective (8.48 QALYs) and less costly 
($908,365) compared to both natalizumab (8.46 QALYs and $1,048,599) and fingolimod 
(7.96 QALYs and $1,085,814) [40]. Similar results were reported in the analysis conducted 
by the Canadian Agency for Drugs and Technologies in Health [39], in which ocrelizumab 
reported a lower cost ($1,001,296) and higher efficacy (12.79 QALYs) compared to fingoli-
mod ($1,007,689 and 12.24 QALYs), and a lower cost with slightly lower efficacy compared 
to natalizumab ($1,127,130 and 12.99 QALYs) that makes ocrelizumab the cost-effective 
treatment option.
No data are published about the budget impact associated to ocrelizumab in Italy or other 
countries. Our study is the first providing information on ocrelizumab budget impact, show-
ing a possible reduction in RMS costs of € 21 million (2.6%) in a 3-year time horizon, giving 
also the alternative possibility to treat more MS patients at the same overall budget impact. As 
showed in our analysis, the reduction of the budget was associated to the use of ocrelizumab 
instead of fingolimod and natalizumab. These results look in line with the cost-effectiveness 
analyses performed in other countries, where ocrelizumab frequently resulted less expensive 
Figure 3. Budget estimated for each treatment in the two scenario and budget impact estimation for each simulated year
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than natalizumab and fingolimod [38-40]. However, new budget impact analyses are required 
to confirm these results in other countries.
Among limitations of this study, some reside on the data source for treatments efficacy. 
The model based the treatment efficacy (relapse rate and disease progression) on a NMA 
conducted on the DMTs clinical trials [24]. Further, also the probability of treatment inter-
ruption for any causes was based on the same NMA. Clinical trials included in the NMA 
had usually a short-term follow-up (maximum 2 years) compare to the disease duration 
and the simulation time-horizon. These data need to be updated with longer follow-up to 
understand the possible relative efficacy of the treatment included. However, using indirect 
comparison analysis is the recommended approach in the guidelines to manage missing di-
rect comparison between treatments [41]. Another limitation is associated to the exclusion 
of alemtuzumab within the treatments. Alemtuzumab presents some different characteristics 
compared to the other second line DMTs that make difficult its inclusion in our evaluation. 
All second-line DMTs need to be administered chronically until the lack of efficacy or safe-
ty issue development, while alemtuzumab is provided initially as 2 annual treatment courses 
and in case of clinical or magnetic resonance imaging disease activity retreatment is neces-
sary after the initial 2 annual treatment courses [42]. Based on the available data, patients 
treated with alemtuzumab reported retreatment in 36.1% in years 3, 4, or 5 (25.6% received 
1 additional course, 9.0% received 2 additional courses, and 1.5% received 3 additional 
courses) [43]. While over 10-year time horizon, 43%, 12%, and 10% received three, four, or 
five courses of alemtuzumab, respectively [44]. These data make some issues in modeling 
efficacy and costs over a lifetime time horizon, particularly considering the simulation of 
treatment effect over time, treatment discontinuation and efficacy of retreatment [45]. Based 
on our model structure and long-term treatment effect and discontinuation, we decided to 
not include alemtuzumab in this analysis and focused on fingolimod and natalizumab that 
represented the 95% of the second-line DMTs used in Italy, and are chronic treatment as 
ocrelizumab. Based on this approach we include alemtuzumab only in the budget impact 
analysis but we assumed no change in its market share due to the market access of ocreli-
zumab. 
conclusions
The results of our cost-effectiveness and budget impact models reported ocrelizumab as an 
effective, efficacy, and efficient treatment in patients with RMS, who failed a first line DMT. 
Further, ocrelizumab showed the possibility to have a positive impact on the Italian NHS 
budget with a cost-saving of € 21 million over a 3-year time horizon. The results of the model 
need to be confirmed by further economic evaluations based on ocrelizumab long-term data 
and including all DMTs.
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